US Food and Drug Administration Approval of Aducanumab-Is Amyloid Load a Valid Surrogate End Point for Alzheimer Disease Clinical Trials?
- PMID: 34515750
- DOI: 10.1001/jamaneurol.2021.3126
US Food and Drug Administration Approval of Aducanumab-Is Amyloid Load a Valid Surrogate End Point for Alzheimer Disease Clinical Trials?
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical